An interventional study of HistoSonics® Edison System (US) in Localised or Metastatic Renal Cell Carcinoma, sponsored by The University of Hong Kong. Recruiting at 1 site in Hong Kong. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-11-17.
Sponsored by The University of Hong Kong · Not applicable, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 20 studies in Carcinoma, Renal Cell with a site in Hong Kong — 3 open to participants now, 9 under way, 6 of them phase 3. Carcinoma, Renal Cell · Hong Kong.
Among the 20 studies in Carcinoma, Renal Cell with a site in Hong Kong, this one is the 19th largest by planned enrollment of the 19 interventional ones that give a count, is the only one that started in 2026, is one of 3 with no phase, and was the 20th registered.
2,039 studies on the registry are indexed under Carcinoma, Renal Cell; 396 are open to participants now.
Browse Carcinoma, Renal Cell studies →3 of the 20 studies in Carcinoma, Renal Cell with a site in Hong Kong are open now. Recruiting first, the newest first:
Merck Sharp & Dohme LLC · Sites in Hong Kong, United States, Argentina and 21 more countries
Ages 18+
Chinese University of Hong Kong · Sites in Hong Kong
Ages 18+
A study can be open while its sites in Hong Kong have not opened yet or have stopped. Only those recruiting at a site in Hong Kong →
Of the 309 Carcinoma, Renal Cell studies recruiting now, 256 (83%) set no upper age limit and 18 (6%) stop at 75 or younger; 21 take children under 18; 20 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
20 studies; the count open now beside each. This study's row is marked.
First in 2005; this study’s year is marked. 1 started in 2026.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 15 is below the median of 43 across 1,566 interventional studies indexed under Carcinoma, Renal Cell.
Median enrollment 317 across the 19 interventional studies. Of the 10 that completed or were terminated, 8 (80%) have results posted.
This tab as a report to print or save as PDF → With an account.
16 of 20 have an industry lead sponsor. The 10 most frequent:
The University of Hong Kong is the lead sponsor of 1,295 studies on the registry; 351 are open to participants now.
Of its 9 completed or terminated interventional studies of FDA-regulated products, 0 (0%) have results posted.
The University of Hong Kong has 1 study filed under Carcinoma, Renal Cell — fewer than ten, so there is no comparison to draw.
3 of the studies in Carcinoma, Renal Cell with a site in Hong Kong that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT05678673Phase 3ExelixisStudy of XL092 + Nivolumab vs Sunitinib in Subjects With Advanced or Metastatic Non-Clear Cell Renal Cell Carcinoma | 2026-12-15 |
| NCT03221335Chinese University of Hong KongEUS-guided RFA for Solid Abdominal Neoplasms | 2027-04 |
| NCT05544929Novartis PharmaceuticalsA Study of Safety and Efficacy of KFA115 Alone and in Combo With Pembrolizumab in Patients With Select Advanced Cancers | 2027-10-05 |
Add all 3 to your calendar (.ics) → With an account.
Among the 20 studies in Carcinoma, Renal Cell with a site in Hong Kong, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The project will be a pilot study in localised or metastatic renal cell carcinoma, assessing safety, local control, and exploratory immune endpoints. Outcomes from this work will inform rational combinations with targeted agents and immune checkpoint blockade and may define a new, image-guided, non-invasive modality for renal cell carcinoma. If successful, histotripsy could become a new non-thermal, local therapy for renal cell carcinoma with dual benefits of debulking and immune activation achieving strong clinical and scientific impact.
Study Design and Methodology
This study will enrol 15 patients with localised or metastatic renal cell carcinoma. Patients will be identified from clinic, and undergo a comprehensive evaluation, including imaging studies and laboratory tests, to confirm the diagnosis and assess their eligibility for histotripsy.
Procedure
Histotripsy will be performed by dedicated team of oncologist, urologist and radiologist who have undergone accredited training on Histotripsy aiming to achieve the best clinical outcomes and ensure patient safety. Patients are typically placed under general anaesthesia (GA) or monitored anaesthesia care (MAC) with real-time monitoring. The component of the Histotripsy machine that generates sound waves is positioned within a soft, flexible membrane filled with specially treated water, which rests on the patient's abdomen and facilitates the transmission of sound waves to the targeted tissue. The procedure will be delivered in a single session or multiple sessions by ultrasound, depending on the size and location of tumours.
Assessment
Patients will be invited to complete a questionnaire for pain score assessment before and after histotripsy.
Blood samples will be collected for clinical evaluation and laboratory tests at baseline, followed by 1-day, 30-day, 60-day, and 90-day after histotripsy, aligned with existing feasibility and trial schedules. Blood tests and cellular analysis such as complete blood profile, liver and renal function tests, tumour markers, immune markers and biomarkers etc. will be performed each time. Patients will be asked for consent for 15ml blood collection for the cellular analysis.
Serial post-histotripsy imaging (CT/MRI) will also be arranged. Imaging within 36-hour after histotripsy will be proceeded to confirm the ablation zone and assess complications. Post-procedure imaging at 1-, 3-, and 6-month will help to capture the sustainability of treatment effect, then per standard of care thereafter.
Admission and follow-up
Similar to other minimal invasive treatments, patients will be admitted one day prior, or on the day of procedure. After the procedure of histotripsy, patients may experience some discomfort in the treated area, but patients can often return to normal activities quickly. They could be discharged in few hours, or the next day after procedure depending on clinical conditions.
After discharge, follow-up consultations and assessments such as regular imaging and blood tests will be arranged accordingly.
Potential risk and discomfort
Blood drawn for laboratory tests can cause bruising at or near the site where the needle enters the vein and thus increase the risk of infection. Risks related to imaging scans will be explained prior to the procedures by the related doctors or medical professionals.
Procedure risk related to Histotripsy includes skin erythema or superficial burn injury, infection, bleeding, renal dysfunction, and abdominal wall injury or burn. Adverse post treatment event includes bleeding, infection, damage to surrounding structures etc. The medical team will monitor closely and response promptly.
Short-term effects
Potential serious complications
Long-term complications
In the event of complications arising from the study treatment, patients will be treated accordingly or referred for standard treatment and care.
Statistical analysis
Analysis will be performed for the 15 participants recruited, with basic demography (age, sex, medical history etc.), clinical evaluation, laboratory tests, imaging, treatment outcome with associated complication.
DATA AND BIOLOGICAL SAMPLES HANDLING
Patients will be invited to register on the Histotripsy (HistoSonics○R) Registry in Gleneagles Hospital Hong Kong for data collection. Collected personal and study data will be anonymised and stored in a password protected, encrypted database with the principal investigator and delegated staff in the long run. The principal investigator will be responsible for the safekeeping. Only investigators and delegated staff can have right to gain access to the data. All collected data and biological samples will be stored permanently for future review in histotripsy related research. Unused biological samples will be destroyed and discarded upon request, however, the results will remain a part of the overall research data if part of the sample has been proceeded.
Consent
Written voluntary consents will be obtained after full explanation of the study to patients before agreement of the histotripsy procedure.
Conflicts of interests
All investigators and funding bodies have no financial interests in the study.
Research ethics
The study will be performed in accordance with ethical principles that have their origin in the Declaration of Helsinki and are consistent with ICH/Good Clinical Practice, and applicable regulatory requirements Patient data protection.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).
Your pathology report is the document that shows this.
A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.
Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².
Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.
The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.
Histologically or cytologically confirmed
The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).
Your pathology report is the document that shows this.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Biopsy and archival tissue
A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.
Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Metastases
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECOG performance status
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
GFR and eGFR (kidney filtering)
GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².
Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Life expectancy
The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Device: HistoSonics® Edison System (US)
Patients with be admitted to Gleneages Hospital for histotripsy procedure. Pre-produce anaestetic assessment will occur and patients will be treated under general anasestetic with jet ventilation. Patient will be positioned in the left or right lateral position and a water tank will be placed over the patient's loin area. The histotripsy ultrasound and treatment head will be placed inside the water tank and image-guided histotripsy ablation of the kidney tumor will be performed. The expected length of hospital stay is 1 day after operation. Patient will undergo follow up with regular imaging up to 6 months.
To assess efficacy
Successful treatment percentage at 90 days on MRI/CT post-procedure
Time frame: 90 days post procedure
To assess treatment safety
Freedom from index procedure related major complications, defined by Clavien-Dindo Classification Grade 3 or higher
Time frame: At 30 days
Pain score assessment before and after histotripsy
Time frame: At baseline (after inpatient admission and before histotripsy) and day 2 (before discharge of patient) on a 11-point scale Numeric Pain Rating Scale (NPRS).
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: No
Started Oct 2026 (actual). Primary completion is estimated for Oct 2028, 24 months after the start.
Of 119 non-industry interventional studies with no phase under Carcinoma, Renal Cell, half reached primary completion within 48 months of starting (the median), counting those still running; a quarter within 24 and three quarters within 114. This study's planned 24 months is below that.
Counting every sponsor, half of 126 studies reached it within 45 months; a quarter within 22 and three quarters within 114.
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.